


Please type a plus sign (+) inside this box 

PTO/SB/08A/B (08-03)  
Approved for use through 07/31/2006, OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/558,159
				Filing Date	November 22, 2005
				First Named Inventor	JAMIL, Haris
				Group Art Unit	
Examiner Name					
Sheet	1	of	6	Attorney Docket Number	239615

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Filing Date, if appropriate MM-DD-YYYY
		Document Number	Kind Code			
	AA	US- 4,774,085		09-27-1988	Fidler	
	AB	US- 4,952,408		08-28-1990	Rahman	
	AC	US- 5,424,073		06-13-1995	Rahman et al.	
	AD	US- 5,648,090		07-15-1997	Rahman et al.	
	AE	US- 5,744,460		04-28-1998	Muller et al.	
	AF	US- 6,056,973		05-02-2000	Allen et al.	
	AG	US- 6,090,955		07-18-2000	Reszka et al.	
	AH	US- 6,126,965		10-03-2000	Kasid et al.	
	AI	US- 6,146,659		11-14-2000	Rahman	
	AJ	US- 6,333,314		12-25-2001	Kasid et al.	
	AK	US- 6,461,637		10-08-2002	Rahman	
	AL	US- 6,469,058		10-22-2002	Grove et al.	
	AM	US- 6,559,129		05-06-2003	Kasid et al.	
	AN	US- 2003/0035830	A1	02-20-2003	Rahman et al.	
	AO	US- 2003/0215489	A1	11-20-2003	Kasid et al.	
	AP	US- 2003/0215492	A1	11-20-2003	Ahmad et al.	
	AQ	US- 2003/0219476	A1	11-27-2003	Ahmad et al.	
	AR	US- 2003/0225023	A1	12-04-2003	Kasid et al.	
	AS	US- 2003/0228317	A1	12-11-2003	Gokhale et al.	
	AT	US- 2003/0229040	A1	12-11-2003	Kasid et al.	
	AU	US- 2004/0005603	A1	01-08-2004	Kasid et al.	
	AV	US- 2004/0082771	A1	04-29-2004	Kasid et al.	
	AW	US- 2004/0106571	A1	06-03-2004	Kasid et al.	
	AX	US- 2004/0115714	A1	06-17-2004	Kasid et al.	
	AY	US- 2004/0248218	A1	12-09-2004	Kasid et al.	


\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature	/Gollamudi Kishore/	Date Considered	11/02/2009
--------------------	---------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.K./

Please type a plus sign (+) inside this box → PTO/SB/08A/B (08-03)  
Approved for use through 07/31/2008. OMB 0651-0031  
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Substitution for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/558,159	
			Filing Date	November 22, 2005	
			First Named Inventor	JAMIL, Haris	
			Group Art Unit		
Examiner Name					
Sheet	2	of	6	Attorney Docket Number	239615

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Filing Date, if appropriate MM-DD-YYYY
		Document Number	Kind Code			
	AZ	US- 2005/0002918	A1	01-06-2005	Strauss et al.	
	BA	US- 2005/0019387	A1	01-27-2005	Rahman et al.	
	BB	US- 2005/0148528	A1	07-07-2005	Gately	
	BC	US- 2005/0153297	A1	07-14-2005	Ahmad et al.	
	BD	US- 2005/0181037	A1	08-18-2005	Ahmad et al.	
	BE	US- 2005/0202074	A1	09-15-2005	Rahman	
	BF	US- 2005/0238706	A1	10-27-2005	Ahmad et al.	
	BG	US- 2005/0249795	A1	11-10-2005	Zhang et al.	
	BH	US- 2005/0266068	A1	12-01-2005	Ahmad et al.	
	BI	US- 2005/0277611	A1	12-15-2005	Ahmad et al.	
	BJ	US- 09/354,109			Kasid et al.	07-15-1999
	BK	US- 09/930,283			Kasid et al.	08-16-2001
	BL	US- 10/056,210			Kasid et al.	01-28-2002
	BM	US- 10/239,598			Rahman	10-25-2000
	BN	US- 10/680,313			Kasid et al.	10-06-2003
	BO	US- 10/786,866			Zhang et al.	02-24-2004
	BP	US- 10/842,189			Strauss et al.	05-09-2004
	BQ	US- 11/010,158			Kasid et al.	12-10-2004
	BR	US- 11/061,044			Ahmad et al.	02-18-2005
	BS	US- 11/105,970			Ahmad et al.	04-14-2005
	BT	US- 11/106,406			Ahmad et al.	04-14-2005
	BU	US- 11/177,194			Ahmad et al.	07-08-2005
	BV	US- 11/196,123			Zhang et al.	08-03-2005
	BW	US- 11/201,810			Bhamidipati et al.	08-11-2005
	BX	US- 11/287,530			Jamil et al.	11-22-2005

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.96(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature	/Gollamudi Kishore/	Date Considered	11/02/2009
--------------------	---------------------	-----------------	------------

1 EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.K./

Please type a plus sign (+) inside this box → 

PTO/SB/08A/B (08-03)  
Approved for use through 07/31/2008. OMB 0851-0031  
Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/558,159
				Filing Date	November 22, 2005
				First Named Inventor	JAMIL, Haris
				Group Art Unit	
Examiner Name					
Sheet	3	of	6	Attorney Docket Number	239615


U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Filing Date, if appropriate MM-DD-YYYY
		Document Number	Kind Code			
	BY	US- 60/041,192			Kasid et al.	03-21-1997
	BZ	US- 60/165,236			Puri et al.	11-11-1999
	CA	US- 60/229,842			Puri et al.	08-31-2000
	CB	US- 60/241,069			Rahman et al.	10-16-2000
	CC	US- 60/247,306			Rahman et al.	11-09-2000
	CD	US- 60/264,062			Kumar et al.	01-26-2001
	CE	US- 60/281,779			Kasid et al.	04-06-2001
	CF	US- 60/281,780			Kasid et al.	04-06-2001
	CG	US- 60/281,785			Kasid et al.	04-06-2001
	CH	US- 60/281,796			Kasid et al.	04-06-2001
	CI	US- 60/294,285			Rahman et al.	05-29-2001
	CJ	US- 60/314,959			Rahman et al.	08-24-2001
	CK	US- 60/332,477			Strauss et al.	11-09-2001
	CL	US- 60/371,116			Kasid et al.	04-10-2002
	CM	US- 60/371,126			Kasid et al.	04-10-2002
	CN	US- 60/382,031			Gokhale et al.	05-22-2002
	CO	US- 60/382,411			Gately	05-20-2002
	CP	US- 60/383,340			Ahmad et al.	05-24-2002
	CQ	US- 60/384,222			Ahmad et al.	05-29-2002
	CR	US- 60/404,668			Rahman et al.	08-20-2002
	CS	US- 60/405,378			Zhang et al.	08-23-2002
	CT	US- 60/419,277			Ahmad et al.	10-16-2002
	CU	US- 60/429,285			Ahmad et al.	11-26-2002
	CV	US- 60/438,659			Ahmad et al.	01-07-2003
	CW	US- 60/444,958			Zhang et al.	02-03-2003

- \* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a).(3).  
 + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a).(3).

Examiner Signature	/Gollamudi Kishore/	Date Considered	11/02/2009
--------------------	---------------------	-----------------	------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.K./

Please type a plus sign (+) inside this box → 

PTO/SB/08A/B (08-03)  
Approved for use through 07/31/2006. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/558,159	
			Filing Date	November 22, 2005	
			First Named Inventor	JAMIL, Haris	
			Group Art Unit		
Examiner Name					
Sheet	4	of	6	Attorney Docket Number	239615

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Filing Date, if appropriate MM-DD-YYYY
		Document Number	Kind Code			
	CX	US- 60/446,895			Bhamidipati et al.	02-11-2003
	CY	US- 60/457,898			Gately et al.	03-26-2003
	CZ	US- 60/467,331			Ahmad et al.	05-02-2003
	DA	US- 60/472,664			Jamil et al.	05-22-2003
	DB	US- 60/480,669			Jamil et al.	06-23-2003
	DC	US- 60/495,260			Jamil et al.	08-13-2003
	DD	US- 60/514,658			Ahmad et al.	10-27-2003
	DE	US- 60/535,042			Ahmad et al.	01-07-2004
	DF	US- 60/556,843			Ahmad et al.	03-27-2004
	DG	US- 60/557,232			Ahmad et al.	03-29-2004
	DH	US- 60/577,414			Hussey et al.	06-05-2004
	DI	US- 60/583,833			Ahmad et al.	06-29-2004

FOREIGN PATENT DOCUMENTS									
Examiner Initials <sup>a</sup>	Cite No.	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	Translation Provided?	
		Office	Number	Kind Code				Yes	No
	DJ	DE	39 36 328	A	05-02-1991	Schering AG			
	DK	DE	101 31 796	A	01-16-2003	Beiersdorf AG			
	DL	WO	93/18751	A	09-30-1993	Georgetown University			
	DM	WO	98/43095	A	10-01-1998	Georgetown University			
	DN	WO	00/01366	A	01-13-2000	NeoPharm, Inc.			
	DO	WO	01/34130	A	05-17-2001	Boulikas			
	DP	WO	01/34116	A	05-17-2001	P.N. Gerolymatos S.A.			
	DQ	WO	01/70220	A	09-27-2001	NeoPharm, Inc.			
	DR	WO	01/95946	A	12-20-2001	Transgene S.A.			


\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature	/Gollamudi Kishore/	Date Considered	11/02/2009
--------------------	---------------------	-----------------	------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.K./

Please type a plus sign (+) inside this box → PTO/SB/08A/B (08-03)  
Approved for use through 07/31/2006. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/558,159
				Filing Date	November 22, 2005
				First Named Inventor	JAMIL, Haris
				Group Art Unit	
Examiner Name					
Sheet	5	of	6	Attorney Docket Number	239615

FOREIGN PATENT DOCUMENTS									
Examiner's Initials*	Cite No.	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	Translation Provided?	
		Office	Number	Kind Code				Yes	No
	DS	WO	02/32400	A	04-25-2002	NeoPharm, Inc.			
	DT	WO	02/058622	A	08-01-2002	NeoPharm, Inc.			
	DU	WO	02/059337	C2	08-01-2002	Georgetown Univ. School of Medicine			
	DV	WO	02/081639	A	10-17-2002	Georgetown Univ.			
	DW	WO	02/081640	A	10-17-2002	Georgetown Univ.			
	DX	WO	02/081641	A	10-17-2002	Georgetown Univ.			
	DY	WO	02/081642	A	10-17-2002	Georgetown Univ.			
	DZ	WO	03/018018	A	03-06-2003	NeoPharm, Inc.			
	EA	WO	03/030864	A	04-17-2003	NeoPharm, Inc.			
	EB	WO	03/039600	A	05-15-2003	NeoPharm, Inc.			
	EC	WO	03/070221	A	08-28-2003	Georgetown Univ.			
	ED	WO	03/099213	A	12-04-2003	NeoPharm, Inc.			
	EE	WO	03/099830	A	12-04-2003	NeoPharm, Inc.			
	EF	WO	03/102011	A	12-11-2003	NeoPharm, Inc.			
	EG	WO	2004/017940	A	03-04-2004	NeoPharm, Inc.			
	EH	WO	2004/017944	A	03-04-2004	NeoPharm, Inc.			
	EI	WO	2004/035523	A	04-29-2004	NeoPharm, Inc.			
	EJ	WO	2004/039817	A	05-13-2004	NeoPharm, Inc.			
	EK	WO	2004/062569	A	07-29-2004	NeoPharm, Inc.			
	EL	WO	2004/069224	A	08-19-2004	NeoPharm, Inc.			
	EM	WO	2004/071466	A	08-26-2004	NeoPharm, Inc.			
	EN	WO	2004/087758	A	10-14-2004	NeoPharm, Inc.			
	EO	WO	2005/000266	A	01-06-2005	NeoPharm, Inc.			

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a).(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a).(3).

Examiner Signature	/Gollamudi Kishore/	Date Considered	11/02/2009
--------------------	---------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.K./

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/558,159	
			Filing Date	November 22, 2005	
			First Named Inventor	JAMIL, Haris	
			Group Art Unit		
Examiner Name					
Sheet	6	of	6	Attorney Docket Number	239615

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	Translation Provided?	
		Office	Number	Kind Code				Yes	No
	EP	WO	2005/000318	A	01-06-2005	NeoPharm, Inc.			
	EQ	WO	2005/042028	A	05-12-2005	NeoPharm, Inc.			
	ER	WO	2005/067632	A	07-28-2005	NeoPharm, Inc.			

OTHER - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Translation Provided?	
			Yes	No
	ES	CAPONIGRO et al., "Raltitrexed/5-fluorouracil-based combination chemotherapy regimens in anticancer therapy," <i>Anti-Cancer Drugs</i> , 12 (6), 489-497 (July 2001).		
	ET	DAMON et al., "Advances in rational combination chemotherapy," <i>Cancer Invest.</i> , 4, 421-444 (1986).		
	EU	LEWIS et al., "Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed," <i>Cancer Chemother. Pharmacol.</i> , 50, 257-265 (2002).		
	EV	PARK, "Liposome-based drug delivery in breast cancer treatment," <i>Breast Cancer Res.</i> , 4 (3), 95-99 (2002).		
	EW	PATHAK et al., "Potentiation of the effect of paclitaxel and carboplatin by antioxidant mixture on human lung cancer H520 cells," <i>J. Am. Coll. Nutr.</i> , 21 (5), 416-421 (2002).		
	EX	RICCI et al., "Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens," <i>Cancer</i> , 95, 1444-1450 (2002).		
	EY	SOCINSKI et al., "Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated stage IIIB/IV nonsmall cell lung carcinoma," <i>Cancer</i> , 95, 1520-1527 (2002).		
	EZ	THIGPEN, "The role of gemcitabine-based doublets in the management of ovarian carcinoma." <i>Semin. Oncol.</i> , 29 (1 Suppl. 1), 11-16 (2002).		

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature	/Gollamudi Kishore/	Date Considered	11/02/2009
--------------------	---------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.